Fujita, Buntaro

[["dc.bibliographiccitation.firstpage","219"],["dc.bibliographiccitation.lastpage","239"],["dc.contributor.author","Fujita, Buntaro"],["dc.contributor.author","Tiburcy, Malte"],["dc.contributor.author","Ensminger, Stephan"],["dc.contributor.author","Zimmermann, Wolfram-Hubertus"],["dc.contributor.editor","Ieda, Masaki"],["dc.contributor.editor","Zimmermann, Wolfram-Hubertus"],["dc.date.accessioned","2019-02-27T13:40:08Z"],["dc.date.available","2019-02-27T13:40:08Z"],["dc.date.issued","2017"],["dc.description.abstract","Heart muscle restoration with in vitro engineered tissue constructs is an exciting and rapidly advancing field. Feasibility, safety, and efficacy data have been obtained in animal models. First clinical trials are on the way to explore the therapeutic utility of cell-free and non-contractile cell-containing grafts. Engineering of contractile patches according to current good manufacturing practice (cGMP) for bona fide myocardial re-muscularization and scalability to address clinical demands remains challenging. Proof-of-concept for solutions to address obvious technical hurdles exists, and it can be anticipated that the first generation of clinically applicable engineered heart muscle (EHM) grafts will become available in the near future. Foreseeable, but likely manageable risks include arrhythmia induction and teratoma formation. Remaining biomedical challenges pertain to the requirement of immune suppression and the strategic approach to optimize immune suppression without subjecting the target patient population to an unacceptable risk. This chapter summarizes the current state of tissue-engineered heart repair with a special emphasis on knowledge gained from in vitro and in vivo studies as well as issues pertaining to transplant immunology and cGMP process development."],["dc.identifier.doi","10.1007/978-3-319-56106-6_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57646"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/185"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.publisher","Springer"],["dc.publisher.place","Cham, Switzerland"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | C04: Fibroblasten-Kardiomyozyten Interaktion im gesunden und erkrankten Herzen: Mechanismen und therapeutische Interventionen bei Kardiofibroblastopathien"],["dc.relation.crisseries","Cardiac and Vascular Biology"],["dc.relation.doi","10.1007/978-3-319-56106-6"],["dc.relation.isbn","978-3-319-56104-2"],["dc.relation.isbn","978-3-319-56106-6"],["dc.relation.ispartof","Cardiac Regeneration"],["dc.relation.ispartofseries","Cardiac and Vascular Biology"],["dc.relation.issn","2509-7830"],["dc.relation.issn","2509-7849"],["dc.relation.workinggroup","RG Tiburcy (Stem Cell Disease Modeling)"],["dc.relation.workinggroup","RG Zimmermann (Engineered Human Myocardium)"],["dc.title","State-of-the-Art in Tissue-Engineered Heart Repair"],["dc.type","book_chapter"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","78"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Current Cardiology Reports"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Fujita, Buntaro"],["dc.contributor.author","Zimmermann, Wolfram-Hubertus"],["dc.date.accessioned","2018-04-23T11:49:18Z"],["dc.date.available","2018-04-23T11:49:18Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose of Review This review provides an overview of the current state of tissue-engineered heart repair with a special focus on the anticipated modes of action of tissue-engineered therapy candidates and particular implications as to transplant immunology. Recent Findings Myocardial tissue engineering technologies have made tremendous advances in recent years. Numerous different strategies are under investigation and have reached different stages on their way to clinical translation. Studies in animal models demonstrated that heart repair requires either remuscularization by delivery of bona fide cardiomyocytes or paracrine support for the activation of endogenous repair mechanisms. Tissue engineering approaches result in enhanced cardiomyocyte retention and sustained remuscularization, but may also be explored for targeted paracrine or mechanical support. Some of the more advanced tissue engineering approaches are already tested clinically; others are at late stages of pre-clinical development. Process optimization towards cGMP compatibility and clinical scalability of contractile engineered human myocardium is an essential step towards clinical translation. Long-term allograft retention can be achieved under immune suppression. HLA matching may be an option to enhance graft retention and reduce the need for comprehensive immune suppression. Summary Tissue-engineered heart repair is entering the clinical stage of the translational pipeline. Like in any effective therapy, side effects must be anticipated and carefully controlled. Allograft implantation under immune suppression is the most likely clinical scenario. Strategies to overcome transplant rejection are evolving and may further boost the clinical acceptance of tissue-engineered heart repair."],["dc.identifier.doi","10.1007/s11886-017-0892-4"],["dc.identifier.gro","3142520"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13675"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/174"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | C04: Fibroblasten-Kardiomyozyten Interaktion im gesunden und erkrankten Herzen: Mechanismen und therapeutische Interventionen bei Kardiofibroblastopathien"],["dc.relation","SFB 1002 | S01: In vivo und in vitro Krankheitsmodelle"],["dc.relation.issn","1523-3782"],["dc.relation.workinggroup","RG Zimmermann (Engineered Human Myocardium)"],["dc.title","Myocardial Tissue Engineering for Regenerative Applications"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.subtype","overview_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","197"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","199"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Fujita, B."],["dc.contributor.author","Zimmermann, W.-H."],["dc.date.accessioned","2018-04-23T11:49:22Z"],["dc.date.available","2018-04-23T11:49:22Z"],["dc.date.issued","2017"],["dc.description.abstract","There is a pressing need for the development of advanced heart failure therapeutics. Current state‐of‐the‐art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell‐derived cardiomyocytes via tissue‐engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue‐engineered heart repair with a focus on engineered heart muscle (EHM)."],["dc.identifier.doi","10.1002/cpt.724"],["dc.identifier.gro","3142525"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13681"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/173"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | C04: Fibroblasten-Kardiomyozyten Interaktion im gesunden und erkrankten Herzen: Mechanismen und therapeutische Interventionen bei Kardiofibroblastopathien"],["dc.relation","SFB 1002 | S01: In vivo und in vitro Krankheitsmodelle"],["dc.relation.issn","0009-9236"],["dc.relation.workinggroup","RG Zimmermann (Engineered Human Myocardium)"],["dc.title","Engineered Heart Repair"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.subtype","overview_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Interactive Cardiovascular and Thoracic Surgery"],["dc.contributor.author","Fujita, Buntaro"],["dc.contributor.author","Zimmermann, Wolfram-Hubertus"],["dc.date.accessioned","2020-12-10T18:19:16Z"],["dc.date.available","2020-12-10T18:19:16Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1093/icvts/ivy208"],["dc.identifier.eissn","1569-9285"],["dc.identifier.issn","1569-9293"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75184"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Myocardial tissue engineering strategies for heart repair: current state of the art"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","P2545"],["dc.bibliographiccitation.firstpage","533"],["dc.bibliographiccitation.issue","suppl_1"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Soong, P. L."],["dc.contributor.author","Sur, S."],["dc.contributor.author","Fujita, B."],["dc.contributor.author","Grishina, E."],["dc.contributor.author","Kuzyakova, M."],["dc.contributor.author","Tiburcy, M."],["dc.contributor.author","Zimmermann, W. H."],["dc.date.accessioned","2019-02-27T09:52:25Z"],["dc.date.available","2019-02-27T09:52:25Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/eurheartj/ehx502.P2545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57635"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/178"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | C04: Fibroblasten-Kardiomyozyten Interaktion im gesunden und erkrankten Herzen: Mechanismen und therapeutische Interventionen bei Kardiofibroblastopathien"],["dc.relation.issn","0195-668X"],["dc.relation.workinggroup","RG Tiburcy (Stem Cell Disease Modeling)"],["dc.relation.workinggroup","RG Zimmermann (Engineered Human Myocardium)"],["dc.title","Inducible paracrine release of IGF-1 improves heart muscle thickness and function"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S380"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The Journal of Heart and Lung Transplantation"],["dc.bibliographiccitation.lastpage","S381"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Fujita, B."],["dc.contributor.author","Tiburcy, Malte"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Ensminger, S."],["dc.contributor.author","Zimmermann, Wolfram-Hubertus"],["dc.date.accessioned","2018-11-07T10:25:26Z"],["dc.date.available","2018-11-07T10:25:26Z"],["dc.date.issued","2017"],["dc.identifier.isi","000398839801287"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42860"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","37th Annual Meeting and Scientific Sessions of the International-Society-for-Heart-and-Lung-Transplantation (ISHLT)"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1557-3117"],["dc.relation.issn","1053-2498"],["dc.title","Cardio-Supportive Activity of Human Blood Monocytes in Human Engineered Heart Muscle"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]